(Sharecast News) - Medical diagnostics company Omega said on Wednesday that the UK Rapid Test Consortium has made "significant progress" in developing a Covid-19 lateral flow antibody test that can be used by people in their homes.
As the lead party of the UK-RTC, Omega said its partner Abingdon Health had been developing a Covid-19 rapid test and made solid progress in just "a short period of time".
Omega stated its role as a member of the UK-RTC was unchanged and will provide volume manufacturing capacity of the test once design freeze has been attained by Abingdon.
Chief executive Colin King said: "I am really impressed with the progress Abingdon have made to date with the development in such a short period of time.
"Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK."
As of 1105 BST, Omega shares were down 1.76% at 69.75p.
1 Jun 2015 12:00
Omega Diagnostics reports good progress in infectious disease division
AIM-listed medical diagnostics company Omega has cheered with news of its infectious disease and allergy projects. Within infectious disease it has made three pilot batches of test devices all of which have shown that its Visitect CD4 product is capable of meeting its performance design goals in com
Read more